Cardioprotection with beta-adrenoceptor blockers. Does lipophilicity matter?
about
Beta-Blockers in the Management of Hypertension and/or Chronic Kidney DiseaseCarvedilol and its new analogs suppress arrhythmogenic store overload-induced Ca2+ releaseEffectiveness comparison of cardio-selective to non-selective β-blockers and their association with mortality and morbidity in end-stage renal disease: a retrospective cohort study.Non-β-blocking R-carvedilol enantiomer suppresses Ca2+ waves and stress-induced ventricular tachyarrhythmia without lowering heart rate or blood pressure.Pharmacokinetics of selective β1-adrenergic blocking agents: prescribing implications.Central-acting therapeutics alleviate respiratory weakness caused by heart failure-induced ventilatory overdrive.Changing beta-blockers in heart failure: when is a class not a class?Metoprolol-mediated amelioration of sympathetic nerve sprouting after myocardial infarction.beta-adrenoreceptor blocking and antihypertensive activity of PP-24, a newly synthesized aryloxypropanolamine derivative.Selective beta(1)-adrenoreceptor blocking activity of newly synthesized acyl amino-substituted aryloxypropanolamine derivatives, DPJ 955 and DPJ 890, in rats.Beta-blocking activity of PP-34, a newly synthesized aryloxypropanolamine derivative, and its cardioprotective effect against ischaemia/reperfusion injury in laboratory animals.Predictors of risk for sudden death in childhood hypertrophic cardiomyopathy: the importance of the ECG risk score.Nebivolol attenuates cerebral vasospasm both by increasing endothelial nitric oxide and by decreasing oxidative stress in an experimental subarachnoid haemorrhage.
P2860
Q26825409-808B9A57-31D2-4E9B-BC36-529462972130Q35707246-C437CBAE-9F35-4655-8723-5120BEEA6706Q35969769-2371ACB9-18D9-484C-81ED-7CD3489C9EABQ36992635-9F085B7D-7F9E-4CDF-A3F1-6A4643EBD9B5Q38226352-1E053211-717A-46E3-BED0-6363605389FFQ38780056-B0AC850A-2ADC-42FC-A60D-9B25FD8FFE8AQ43256110-703C0189-4A14-4687-BDE1-BA1B8C256AA6Q45854006-ECE23090-7120-44D2-AADE-AFB14CF5CE3DQ46289424-0056972E-1610-42AB-B7E9-F4600B677610Q46438471-839976DD-1FF8-431B-9CF1-4A14B26EF8EAQ46470312-B02A6448-0E8A-4A01-ABA1-3BEE44A42317Q47134714-087F0D5A-2459-4B81-8467-157649144588Q47818345-11AEDFE1-78B7-4A37-87A6-AA2D539CE68F
P2860
Cardioprotection with beta-adrenoceptor blockers. Does lipophilicity matter?
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Cardioprotection with beta-adrenoceptor blockers. Does lipophilicity matter?
@ast
Cardioprotection with beta-adrenoceptor blockers. Does lipophilicity matter?
@en
Cardioprotection with beta-adrenoceptor blockers. Does lipophilicity matter?
@nl
type
label
Cardioprotection with beta-adrenoceptor blockers. Does lipophilicity matter?
@ast
Cardioprotection with beta-adrenoceptor blockers. Does lipophilicity matter?
@en
Cardioprotection with beta-adrenoceptor blockers. Does lipophilicity matter?
@nl
prefLabel
Cardioprotection with beta-adrenoceptor blockers. Does lipophilicity matter?
@ast
Cardioprotection with beta-adrenoceptor blockers. Does lipophilicity matter?
@en
Cardioprotection with beta-adrenoceptor blockers. Does lipophilicity matter?
@nl
P356
P1476
Cardioprotection with beta-adrenoceptor blockers. Does lipophilicity matter?
@en
P2093
Hjalmarson A
P2888
P356
10.1007/S003950070008
P478
95 Suppl 1
P577
2000-01-01T00:00:00Z
P6179
1045835524